Combination of ivabradine and beta-blockers: Results of an observ | 57118
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

Combination of ivabradine and beta-blockers: Results of an observational study in daily practice in Morocco

3rd World Heart Congress

April 19-20, 2018 Amsterdam, Netherlands

Anass Assaidi

Mohammed VI University of Health Science, Morocco

Posters & Accepted Abstracts: J Clin Exp Cardiology

Abstract :

Introduction: Several studies confirm that combining ivabradine with beta-blockers, reduce more effectively the heart rate in patients with heart failure and/or angina than beta-blockers alone. Methods: Non-interventional cohort study, conducted in Morocco Cardiology clinical practice, in patients with heart failure or angina treated with ivabradine in combination with beta-blockers. The primary outcome, measured at 1 and 4 months, were HR, NYHA classification, and SEATTLE quality of life questionnaire for angina patients. Results: 497 patients were included, their mean age was 65.6?±10.3 years, mean HR was 89.4?±14.5 bpm and 61.6% were male. 10.9% treated with less than the initial beta-blockers dosage, 56.8% under initial dosage, 21.9% under less than recommended dosage and 10.4% under recommended dose. After 4 months, the mean HR showed a significant reduction of 27?±13.8 bpm (p<0.0001) and no statistical significant difference (p=0.46) observed between beta-blockers dosages which was respectively 26.2?±0.8, 28.2?±2, 32.2?±2, and 26.08?±1.3, for initial, recommended, less than initial and less than recommended dosage. 42% of patients became NYHA I, 55% NYHA II, only 4% were NYHA III and no patient remained NYHA IV regardless of BB dosages. There was no-significant difference associated to the BB dose (p=0.53) in the 5 SAQ domain-scores between baseline (V0) and 4 months follow up visit (V2). Conclusion: In this study, ivabradine was effective in reducing HR in CHF and angina patients over a period of 4 months irrespective of the dose of beta-blockers. There was a marked shift from higher to lower NYHA classes independently of the BB administered dose.

Biography :

Anass Assaidi,is a Medical Doctor and an Assistant Professor of Interventional Cardiology at Mohammed VI University of Health Sciences and Cheikh Khalifa ibn Zaid Hospital. He is a Graduate Cardiologyist from Aix Marseille II University and Casablanca Medicine University, got Interuniversity Diploma of "Pediatric and Congenital Cardiology" in 2012 from Aix-Marseille II University, “Echocardiography" from Bordeaux II University and "Endovascular treatment of valvular heart disease" from Paris V University. He is an active member of European, French & Moroccan Societies of Cardiology and Member of the Interventional Cardiology Reflection Group. He participated in many research projects related to cardiovascular diseases and author of several publications.